Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Magnetic resonance imaging with gadolinium-labeled porphysomes
FY 2020-21
Summary
Magnetic resonance imaging (MRI) has developed into one of the most powerful diagnostic tools in biomedicine. However, due to the relatively low sensitivity of MRI for tumor diagnosis, contrast agents (CAs) are used to improve the quality of MR images. Most common MRI CAs use gadolinium (Gd) ions due to its enhancing spatial resolution and brightening effects. Currently, most clinically approved Gd-incorporated CAs show limited efficiency, are non-targeting and are rapidly cleared from the blood. Incorporating Gd ions into nanoparticles has allowed for the ability to load up to hundreds of thousands of Gd ions per structure, modifying it to include tumor targeting, and enhance its multimodality. However, previously designed particles are either toxic, inorganic, or lack multifunctionality. Thus, a safer and more effective Gd-incorporated nanostructure is essential in order to translate such technology into the clinical stages. Porphysome nanovesicles, which were discovered within the Zheng lab, are fully organic and multimodal imaging CAs that can be tracked within the body and deliver drugs to diseased tissues. Recently, porphysome formulations in the lab have included the labelling of Gd, adding MR imaging potential onto the nanoparticles' multimodal imaging toolbox. To test the hypothesis on if porphysomes can act as MRI CAs, I propose to work with a variety of different formulated Gd-labelled porphysomes, testing their efficacy in pancreatic cancer cell and mouse models, with plans of further modifying them to enhance their targeting ability on a specific disease. With porphysomes being on the verge of entering its 1st-in-patient clinical trial, proving they can act as effective MRI CAs will also offer them high clinical translation potential.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449623
Name
Margalik Denis A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Magnetic resonance imaging with gadolinium-labeled porphysomes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Contrast Agents; Dtpa; Gadolinium Complexes; Magnetic Resonance Imaging; Molecular Imaging; Nanoparticle; Porphysome
Abstract
Magnetic resonance imaging (MRI) has developed into one of the most powerful diagnostic tools in biomedicine. However, due to the relatively low sensitivity of MRI for tumor diagnosis, contrast agents (CAs) are used to improve the quality of MR images. Most common MRI CAs use gadolinium (Gd) ions due to its enhancing spatial resolution and brightening effects. Currently, most clinically approved Gd-incorporated CAs show limited efficiency, are non-targeting and are rapidly cleared from the blood. Incorporating Gd ions into nanoparticles has allowed for the ability to load up to hundreds of thousands of Gd ions per structure, modifying it to include tumor targeting, and enhance its multimodality. However, previously designed particles are either toxic, inorganic, or lack multifunctionality. Thus, a safer and more effective Gd-incorporated nanostructure is essential in order to translate such technology into the clinical stages. Porphysome nanovesicles, which were discovered within the Zheng lab, are fully organic and multimodal imaging CAs that can be tracked within the body and deliver drugs to diseased tissues. Recently, porphysome formulations in the lab have included the labelling of Gd, adding MR imaging potential onto the nanoparticles' multimodal imaging toolbox. To test the hypothesis on if porphysomes can act as MRI CAs, I propose to work with a variety of different formulated Gd-labelled porphysomes, testing their efficacy in pancreatic cancer cell and mouse models, with plans of further modifying them to enhance their targeting ability on a specific disease. With porphysomes being on the verge of entering its 1st-in-patient clinical trial, proving they can act as effective MRI CAs will also offer them high clinical translation potential.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Margalik, Denis A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~